Jump to content

New FDA Approval for Met Exon skipping NSCLC

Recommended Posts

New Drug Approval Alert: FDA approves capmatinib (Tabrecta) for Met Exon 14 skipping NSCLC – a mutation seen in 3%-4% of #NSCLC. A companion diagnostic to identify these mutations has also been given the green light. The approval reinforces the need for more comprehensive biomarker testing to identify rare mutations and drive better outcomes.


Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.